[go: up one dir, main page]

WO1999006834A3 - Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands - Google Patents

Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands

Info

Publication number
WO1999006834A3
WO1999006834A3 PCT/US1998/016280 US9816280W WO9906834A3 WO 1999006834 A3 WO1999006834 A3 WO 1999006834A3 US 9816280 W US9816280 W US 9816280W WO 9906834 A3 WO9906834 A3 WO 9906834A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid support
diverse population
antibody
binding molecules
selective
Prior art date
Application number
PCT/US1998/016280
Other languages
English (en)
Other versions
WO1999006834A2 (fr
Inventor
Jeffry D Watkins
William D Huse
Herren Wu
Original Assignee
Ixsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ixsys Inc filed Critical Ixsys Inc
Priority to JP2000505515A priority Critical patent/JP2004503201A/ja
Priority to EP98938377A priority patent/EP1007967A2/fr
Priority to AU86913/98A priority patent/AU8691398A/en
Publication of WO1999006834A2 publication Critical patent/WO1999006834A2/fr
Publication of WO1999006834A3 publication Critical patent/WO1999006834A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé permettant d'identifier une molécule de liaison présentant une affinité sélective pour un ligand. Ce procédé consiste à immobiliser, de manière sélective, une population diverse de molécules de liaison à un support solide, à placer simultanément en contact la population diverse immobilisée sur le support solide avec deux ou plusieurs ligands et à déterminer au moins une molécule de liaison qui se lie, de manière sélective, à un ou plusieurs ligands. En outre, l'invention concerne un procédé permettant d'identifier un anticorps présentant une affinité selective pour un antigène tumoral. Ce procédé consiste à immobiliser, de manière sélective, une population diverse d'anticorps sur un support solide, à placer simultanément en contact la population diverse immobilisée sur le support solide avec deux ou plusieurs antigènes tumoraux et à déterminer au moins un anticorps qui se lit, de manière sélective, avec un ou plusieurs des antigènes tumoraux. L'invention concerne également un polypeptide de liaison isolé présentant une activité sélective pour un antigène tumoral. En outre, la présente invention concerne une région de détermination de la complémentarité ou un fragment fonctionnel de cette dernière d'un anticorps sélectif pour un antigène tumoral.
PCT/US1998/016280 1997-08-04 1998-08-04 Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands WO1999006834A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000505515A JP2004503201A (ja) 1997-08-04 1998-08-04 リガンド特異的結合分子の同定方法
EP98938377A EP1007967A2 (fr) 1997-08-04 1998-08-04 Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands
AU86913/98A AU8691398A (en) 1997-08-04 1998-08-04 Methods for identifying ligand specific binding molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90582597A 1997-08-04 1997-08-04
US08/905,825 1997-08-04

Publications (2)

Publication Number Publication Date
WO1999006834A2 WO1999006834A2 (fr) 1999-02-11
WO1999006834A3 true WO1999006834A3 (fr) 1999-05-14

Family

ID=25421544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/016280 WO1999006834A2 (fr) 1997-08-04 1998-08-04 Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands

Country Status (3)

Country Link
EP (1) EP1007967A2 (fr)
AU (1) AU8691398A (fr)
WO (1) WO1999006834A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US8895475B2 (en) 2000-12-18 2014-11-25 Robert Charles Ladner Focused libraries of genetic packages
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9382535B2 (en) 2000-04-17 2016-07-05 Dyax Corp. Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US9592293B2 (en) 2006-09-08 2017-03-14 Abbvie Inc. Interleukin-13 binding proteins

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1025256A2 (fr) * 1997-10-09 2000-08-09 Ixsys, Incorporated Methode d'identification de ligands a liaison optimale avec un recepteur
US6596539B1 (en) 1997-10-31 2003-07-22 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
EP1235932A2 (fr) 1999-10-08 2002-09-04 Protogene Laboratories, Inc. Procede et appareil destines a produire un grand nombre de reactions au moyen d'une plaque matrice
SE9903895D0 (sv) * 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US9109223B2 (en) 2005-12-23 2015-08-18 Viventia Bio, Inc. Methods for generating and screening fusion protein libraries and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2214708A4 (fr) 2007-10-26 2011-01-12 Centocor Ortho Biotech Inc Vecteurs, cellules hôtes, procédés de production et utilisations
WO2009114815A1 (fr) 2008-03-13 2009-09-17 Dyax Corp Bibliothèques de boîtiers génétiques comprenant de nouvelles conceptions de hc cdr3
US9388510B2 (en) 2008-04-24 2016-07-12 Dyax Corp. Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
CA2722466A1 (fr) 2008-04-29 2009-11-05 Tariq Ghayur Immunoglobulines a double domaine variable et utilisations
CA2723219A1 (fr) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Anticorps contre le recepteur des produits terminaux de glycation avancee (rage) et leurs utilisations
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
CN102612524A (zh) 2009-09-01 2012-07-25 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
WO2011047262A2 (fr) 2009-10-15 2011-04-21 Abbott Laboratories Immunoglobulines à deux domaines variables et utilisations afférentes
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201121568A (en) 2009-10-31 2011-07-01 Abbott Lab Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
CN105037543B (zh) 2010-03-02 2020-11-03 Abbvie 公司 治疗性dll4结合蛋白
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
ES2910305T3 (es) 2010-08-19 2022-05-12 Zoetis Belgium S A Anticuerpos anti-NGF y su uso
RU2013113225A (ru) 2010-08-26 2014-10-10 Эббви Инк. Иммуноглобулины с двумя вариабельными доменами и их применение
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
CA2853258A1 (fr) 2011-10-24 2013-05-02 Abbvie Inc. Agents de liaison immunologique diriges contre la sclerostine
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
PT2890717T (pt) 2012-08-31 2020-04-22 Immunogen Inc Ensaios de diagnóstico e kits para deteção de recetor de folato 1
WO2014071074A2 (fr) 2012-11-01 2014-05-08 Abbvie Inc. Immunoglobulines à domaine variable double anti-vegf/dll4 et leurs utilisations
WO2014100542A1 (fr) 2012-12-21 2014-06-26 Abbvie, Inc. Humanisation d'anticorps à haut rendement
MX2015012824A (es) 2013-03-14 2016-06-24 Abbott Lab Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
JP6505076B2 (ja) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP4364754A3 (fr) 2016-06-08 2025-02-12 AbbVie Inc. Anticorps anti-b7-h3 et conjugués anticorps-médicament
WO2018093841A1 (fr) 2016-11-16 2018-05-24 Janssen Biotech, Inc. Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
US10899842B2 (en) 2016-11-23 2021-01-26 Immunoah Therapeutics, Inc. 4-1BB binding proteins and uses thereof
EP3565845A4 (fr) 2017-01-06 2020-10-07 Biosion, Inc. Anticorps erbb2 et leurs utilisations
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2019025299A1 (fr) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag Procédé d'humanisation à base de structure tridimensionnelle
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019075090A1 (fr) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
MA50580A (fr) 2017-11-06 2020-09-16 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23
BR112020016400A2 (pt) 2018-02-14 2020-12-15 Viela Bio, Inc. Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
BR112021005467A2 (pt) 2018-09-24 2021-06-22 Janssen Biotech, Inc. método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
WO2020128864A1 (fr) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
EP3938390A1 (fr) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
CN113825769A (zh) 2019-03-14 2021-12-21 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
AU2020243588A1 (en) 2019-03-18 2021-10-07 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
US20210347880A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
AU2021276930A1 (en) 2020-05-21 2023-02-02 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
WO2022013745A1 (fr) 2020-07-13 2022-01-20 Janssen Biotech, Inc. Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
US20220073603A1 (en) 2020-07-30 2022-03-10 Janssen Biotech, Inc. Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
BR112023017490A2 (pt) 2021-03-17 2023-11-07 Receptos Llc Métodos de tratamento de dermatite atópica com anticorpos anti il-13

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000295A1 (fr) * 1989-06-30 1991-01-10 Oncogen Limited Partnership Nouveaux anticorps reagissant avec les carcinomes humains
WO1995006067A1 (fr) * 1993-08-21 1995-03-02 Imperial Cancer Research Technology Limited Anticorps monoclonaux utilises pour le diagnostic et le traitement du cancer colorectal
WO1995035374A1 (fr) * 1994-06-21 1995-12-28 Dan Michael D Anticorps monoclonaux humains specifiques vis-a-vis d'antigenes de surface de gliomes, independants du cycle cellulaire
EP0699756A1 (fr) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Anticorps BR96 mutants et équivalents fonctionnels réagissant aux carcinomes humains

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000295A1 (fr) * 1989-06-30 1991-01-10 Oncogen Limited Partnership Nouveaux anticorps reagissant avec les carcinomes humains
WO1995006067A1 (fr) * 1993-08-21 1995-03-02 Imperial Cancer Research Technology Limited Anticorps monoclonaux utilises pour le diagnostic et le traitement du cancer colorectal
WO1995035374A1 (fr) * 1994-06-21 1995-12-28 Dan Michael D Anticorps monoclonaux humains specifiques vis-a-vis d'antigenes de surface de gliomes, independants du cycle cellulaire
EP0699756A1 (fr) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Anticorps BR96 mutants et équivalents fonctionnels réagissant aux carcinomes humains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. YELTON ET AL.: "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.", THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 4, 15 August 1995 (1995-08-15), Baltimore, MD, USA, pages 1994 - 2004, XP002096491 *
I. SANZ ET AL.: "The smaller human VH gene families display remarkably little polymorphism.", THE EMBO JOURNAL, vol. 8, no. 12, 1 December 1989 (1989-12-01), Oxford, GB, pages 3741 - 3748, XP002096490 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382535B2 (en) 2000-04-17 2016-07-05 Dyax Corp. Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US8895475B2 (en) 2000-12-18 2014-11-25 Robert Charles Ladner Focused libraries of genetic packages
US9592293B2 (en) 2006-09-08 2017-03-14 Abbvie Inc. Interleukin-13 binding proteins
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
US9481736B2 (en) 2009-03-05 2016-11-01 Abbvie, Inc. IL-17 binding proteins
US9481735B2 (en) 2009-03-05 2016-11-01 Abbvie Inc. IL-17 binding proteins
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies

Also Published As

Publication number Publication date
AU8691398A (en) 1999-02-22
EP1007967A2 (fr) 2000-06-14
WO1999006834A2 (fr) 1999-02-11

Similar Documents

Publication Publication Date Title
WO1999006834A3 (fr) Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands
CA2162568A1 (fr) Methode et reactif pour la mise a l'essai d'un ligand ou simultanement de plusieurs ligands dans un groupe de ligands predetermine
CA2224674C (fr) Immuno-essai et kit comportant deux reactifs qui sont reticules s'ils adherent a un echantillon a analyser
AU3684197A (en) Assay reagents and devices
DE69503903D1 (de) Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung
JP2003530543A5 (fr)
CA2235269A1 (fr) Anticorps monoclonal br110 et ses utilisations
MX161338A (es) Aparato para inmunoensayos de un enlazante receptor
JP2004528574A5 (fr)
JPH10512371A (ja) 超高速電気分離分析のための組成物、方法、および装置
IL154000A (en) A method that uses antibodies to diagnose arthritis
ATE545019T1 (de) Mikrofluidisches extraktionsverfahren
WO2003046140A3 (fr) Dosage immunologique et kit de detection precoce et simultanee de marqueurs biochimiques dans l'echantillon d'un patient
EP0829723A3 (fr) Méthode de détection homogène pour la détermination de sous-populations d'un analyte
WO2003062444A3 (fr) Systemes matriciels et procedes
CA1194415A (fr) Demi-molecules d'immunoglobulines et procede de production d'anticorps hybrides
CA2067584A1 (fr) Complexe agglutinant en tant que reactif pour le typage sanguin
CA2499355A1 (fr) Preparations, procedes et kits pour la detection d'un antigene sur une cellule et dans un melange biologique
JP2002525607A5 (fr)
AU687932B2 (en) A method for the determinatin of antigens or antibodies in the presence of an immune complex
CA2483408A1 (fr) Dosage en sandwich et kit
WO1999000424A3 (fr) Anticorps et autres molecules de liaison specifiques les antigenes viraux de l'hepatite b
MY137138A (en) Diagnostic reagents and preparing methods thereof
JP2001183375A (ja) 酵素標識抗体
Andersson Antigen-antibody reactions: A study of functional structures and non-immunological interactions.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998938377

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998938377

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998938377

Country of ref document: EP